We are committed to delivering our strategy and creating value for our shareholders.

Verona Pharma can make real a difference to the COPD market, believes CEO Jan-Anders Karlsson

Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.


Watch Jan-Anders Karlsson on Proactive Investors

Latest News

Latest Events

21 February 2020Regulatory
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday,

14 February 2020Company News
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms

7 February 2020Regulatory
Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings

View all regulatory news

© Verona Pharma plc 2020. All rights reserved